NEW YORK, NY / ACCESSWIRE / November 5, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update note on Amarantus BioScience Holdings, Inc. (OTCQX: AMBS).

The report is available here: AMBS November 2015 Update Note. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack's. The report will be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

"We continue to be impressed with developments at AMBS. The recent announcement of ESS partnering with the U.S. Army and Application for Orphan Drug Designation of Eltoprazine bode well for the company over the long term. As a biotechnology company, AMBS works to develop treatment for Parkinson's disease Levodopa-Induced Dyskinesia, Adult Attention Deficit Hyperactivity Disorder, and Retinitis Pigmentosa, as well as developing better diagnostics to test for Alzheimer's disease and Multiple Sclerosis. AMBS also looks to treat severe burns with their recent acquisition of intellectual property rights for the Engineered Skin Substitute product candidate. While their business model is to develop their product candidates through various de-risking milestones, we view AMBS as an attractive high-risk/high-reward investment opportunity in the biotechnology industry. AMBS is also currently in the process of up-listing to the NASDAQ exchange which we see as a positive for the company from a capital markets perspective," stated Ajay Tandon, CEO of SeeThruEquity. "We are maintaining our 12-month price target of $45.34 per share."

Additional highlights from the note are as follows:

Partnering with U.S. Army to expand development of ESS

Engineered Skin Substitute (ESS), a tissue-engineered skin replacement prepared from a patient's skin cells. On October 1, 2015, AMBS announced their intention to strategically focus the majority of its resources on the development of Engineered Skin Substitute for the treatment of rare pediatric diseases. On August 3, 2015, AMBS announced the signing of a Cooperative Research and Development Agreement with the U.S. Army Institute of Surgical Research and Rutgers University, to expand the development of ESS for the treatment of deep partial- and full-thickness burn wounds in adult patients.

MSPrecise(R) proving to be an accurate diagnostic

MSPrecise(R) is a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation. On July 29, 2015, AMBS announced the publication of data on its next generation sequencing (NGS) molecular diagnostic test for multiple sclerosis, MSPrecise(R). In this study, completed in 2013 and now reported in 'GENE,' there is an overall MSPrecise accuracy of 84% in identifying RRMS patients or patients that will develop RRMS, which represents a huge benefit to physicians. MSPrecise(R) exhibits good performance in identifying patients with RRMS irrespective of the time a patient exhibited RRMS.

Successful results for MANF & Eltoprazine

On October 6, 2015, AMBS announced the publication of a study demonstrating the targeted delivery of MANF to brain regions associated with Parkinson's disease in a porcine model. On August 20, 2015, AMBS announced that the U.S. Patent and Trademark Office (USPTO) issued a patent that covers additional intellectual property protection for MANF protein therapy and cell therapy. On October 22, 2015, AMBS announced that it has submitted a request to the US FDA for orphan drug designation (ODD) for eltoprazine in the treatment of levodopa-induced dyskinesia (PD-LID). If successful, this would complete the transition of their therapeutics portfolio into the orphan drug arena.

Maintaining our price target of $45.35

We are maintaining our price target at $45.35 for AMBS, as we believe management is leading the company in the right direction for long-term success. AMBS has been reporting positive results from their therapeutic division, diagnostic division and the expanded development of their Engineered Skin Substitute (ESS).

Please review important disclosures on our website at www.seethruequity.com.

About Amarantus BioScience Holdings, Inc.

Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology and orphan diseases. AMBS' Therapeutics division has development rights to eltoprazine, a small molecule currently in a Phase 2b clinical program for Parkinson's disease levodopa-induced dyskinesia and with the potential to expand into adult ADHD and Alzheimer's aggression. The Company has an exclusive worldwide license to intellectual property rights associated to Engineered Skin Substitute (ESS), an orphan drug designated autologous full thickness skin replacement product in development for the treatment of severe burns currently preparing to enter Phase 2 clinical studies. AMBS owns the intellectual property rights to a therapeutic protein known as mesencephalic-astrocyte-derived neurotrophic factor (MANF) and is developing MANF as a treatment for orphan ophthalmic disorders, initially in retinitis pigmentosa (RP). AMBS also owns the discovery of neurotrophic factors (PhenoGuard(TM)) that led to MANF's discovery.

AMBS' Diagnostics division owns the rights to MSPrecise(R), a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation, has an exclusive worldwide license to the Lymphocyte Proliferation test (LymPro Test(R)) for Alzheimer's disease, which was developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig, and owns intellectual property for the diagnosis of Parkinson's disease (NuroPro).

For further information please visit www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.

About SeeThruEquity

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. The company does not conduct any investment banking or commission based business. SeeThruEquity is approved to contribute its research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks, and distribute its research to its database of opt-in investors. The company also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

For more information visit www.seethruequity.com.

Contact:

Ajay Tandon SeeThruEquity info@seethruequity.com

SOURCE: SeeThruEquity